In a notable development for biomedical innovation, the United States Food and Drug Administration (FDA) achieved a historic milestone in 2023 by approving a record-breaking 71 new medicines. Among these approvals were several revolutionary treatments, including five gene therapies, marking a significant leap forward in the realm of genetic medicine. Additionally, the FDA granted approval for the first CRISPR–Cas9-edited therapy, underscoring the transformative potential of genome editing technologies in treating diseases at their root cause.

One of the most notable achievements of 2023 was the approval of a disease-modifying Alzheimer’s drug, representing a breakthrough in the decades-long quest to combat this debilitating condition. Developed by Eisai and Biogen, the amyloid-fighting antibody Leqembi offers hope to millions affected by Alzheimer’s and their families. Moreover, the approval of Leqembi reflects a renewed focus on addressing complex neurological disorders, signaling a shift towards tackling previously untreatable conditions.

The FDA’s approval landscape in 2023 also highlighted the growing prominence of biologic therapies, with nearly half of the newly approved drugs falling into this category. This trend underscores the increasing utilization of advanced biologic modalities and the expanding capabilities of biotechnology in addressing diverse medical needs. Furthermore, the approval of multiple orphan drugs for rare diseases emphasizes the importance of targeted therapies in addressing unmet medical needs within smaller patient populations.

Despite the remarkable progress made in 2023, the FDA faced challenges such as delays due to COVID-19-related constraints and contentious decision-making processes. However, the agency’s commitment to advancing public health and fostering innovation remained steadfast, paving the way for a new era of medical breakthroughs. As we look ahead to 2024, anticipation mounts for further advancements in drug development and the potential for additional groundbreaking therapies to transform patient care and improve outcomes across a spectrum of diseases.

Check out our mRNA service to expedite your vaccine research
About PackGene

PackGene Biotech is a world-leading CRO and CDMO, excelling in AAV vectors, mRNA, plasmid DNA, and lentiviral vector solutions. Our comprehensive offerings span from vector design and construction to AAV, lentivirus, and mRNA services. With a sharp focus on early-stage drug discovery, preclinical development, and cell and gene therapy trials, we deliver cost-effective, dependable, and scalable production solutions. Leveraging our groundbreaking π-alpha 293 AAV high-yield platform, we amplify AAV production by up to 10-fold, yielding up to 1e+17vg per batch to meet diverse commercial and clinical project needs. Moreover, our tailored mRNA and LNP products and services cater to every stage of drug and vaccine development, from research to GMP production, providing a seamless, end-to-end solution.

Related News

Scientists develop potential stealth cancer therapy

Credit: ACS Central Science (2024). DOI: 10.1021/acscentsci.4c00559Sneaking by cancer's defenses, by disguising tumor-fighting antibodies inside the molecules cancer uses to nourish tumor growth, is the basis of a novel therapy from Yale Cancer Center researchers at...

read more

Related Services

Plasmids GMP Services

Multiple scales & grade of solutions of various kind of plasmids suitable for multiple treatments in a fast and cost effective way.

AAV GMP Services

Ranging from small-scale AAV production, to large-scale AAV cGMP manufacturing for animal studies.
aav icon

Technology Platforms

PackGene’s proprietary π-Alpha™ 293 AAV High-yield Platform increases AAV production by 3 to 8 times that of traditional platforms.